Anti-MYL9 antibody
US10513561B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 11, 2017 |
| Grant date | Dec 24, 2019 |
| Priority date | — |
| Expiry date | Jan 11, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/09
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.